All In Biotech

Drug Trial Radar · NCT06656390

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors

A First-in-Human, Open-Label, Multi-Center Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ALK201 for Injection in Adult Participants With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

202

Planned (sponsor's estimate)

Start

Oct 24, 2024

Primary completion

Oct 22, 2027

Study completion Apr 22, 2028

Sponsor

Sponsor type
Industry
First posted
Oct 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of ALK201. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of ALK201 as a monotherapy in adult participants with Advanced Solid Tumors. The study will also identify recommended dose(s) for subsequent clinical studies of ALK201.

Conditions

  • Advanced Cancer
  • Advanced Solid Tumors

Interventions

  • ALK201Drug

    Administered intravenously, once every 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the safety and tolerability of ALK201 in adult participants with advanced solid tumors; To determine the maximum tolerated dose (MTD); To determine the recommended dose(s) of ALK201 for subsequent clinical studies.Time frame: Approximately 36 months

Locations

38 sites in 3 countries. Site status is shown where the registry gives one.

  • Denver Drug Development Unit

    Denver, Colorado · Recruiting

  • UCF Lake Nona Cancer Center

    Orlando, Florida · Recruiting

  • University Medical Center New Orleans

    New Orleans, Louisiana · Recruiting

  • Sarah Cannon Research Institute Oncology Partners

    Nashville, Tennessee · Recruiting

  • Macquarie University Hospital

    Macquarie, Australia · Recruiting

  • Cancer Care Wollongong

    Wollongong, New South Wales, Australia · Recruiting

  • Sunshine Coast University Private Hospital

    Birtinya, Queensland, Australia · Recruiting

  • Mater Cancer Care Center

    South Brisbane, Queensland, Australia · Recruiting

  • ChongQing University Cancer Hospital

    Chongqing, China · Recruiting

  • Anhui Provincial Cancer Hospital

    Hefei, Anhui, China · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Recruiting

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China · Recruiting

  • The First Affiliated Hospital Of Xiamen University

    Xiamen, Fujian, China · Recruiting

  • Guangdong Province People's Hospital

    Guangzhou, Guangdong, China · Recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

  • Cancer Hospital Of Shantou University Medical College

    Shantou, Guangdong, China · Recruiting

  • Guangxi Medical University Cancer Hospital

    Nanning, Guangxi, China · Recruiting

  • Affiliated Hospital of Chengde Medical University

    Chengde, Hebei, China · Recruiting

  • Harbin Medical University Canser Hospital

    Harbin, Heilongjiang, China · Recruiting

  • The First Affiliated Hospital of Henan University of Science & Technology

    Luoyang, Henan, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • Hubei Cancer Hospital

    Wuhan, Hubei, China · Recruiting

  • Tongji Hospital, Tongji Medical College of Hust

    Wuhan, Hubei, China · Recruiting

  • Union Hospital, Tongji Medical College,Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Recruiting

  • The Central Hospital of Yongzhou

    Yongzhou, Hunan, China · Recruiting

  • The First People's Hospital of Changzhou

    Changzhou, Jiangsu, China · Recruiting

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China · Recruiting

  • The Second Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China · Recruiting

  • Xuzhou Central Hospital ( Southeast University Affiliated Hopstal )

    Xuzhou, Jiangsu, China · Recruiting

  • First Affiliated Hospital of Gannan Medical University

    Ganzhou, Jiangxi, China · Recruiting

  • Liaoning Cancer Hospital

    Shenyang, Liaoning, China · Recruiting

  • Shandong Cancer Hospital

    Jinan, Shandong, China · Recruiting

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China · Recruiting

  • Yunnan Cancer Hospital

    Kunming, Yunnan, China · Recruiting

  • Sir Run Run Shaw Hospital Zhejiang University School of Medical

    Hangzhou, Zhejiang, China · Recruiting

  • The First Affiliated Hospital Zhejiang University School Of Medicine

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.